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ABSTRACT
Objectives Transjugular intrahepatic portosystemic 
stent shunt (TIPSS) is clinically effective in variceal 
bleeding and refractory ascites; however, the cost- 
effectiveness of TIPSS has yet to be evaluated in the UK. 
This study aimed to establish the cost- effectiveness of 
(i) pre- emptive TIPSS versus endoscopic band ligation 
(EBL) in populations with variceal bleeding and (ii) TIPSS 
versus large volume paracentesis (LVP) in refractory 
ascites.
Methods A cost- utility analysis was conducted with 
the perspective including healthcare costs and quality- 
adjusted life years (QALYs). A Markov model was 
constructed with a 2- year time horizon, health states 
for mortality and survival and probabilities for the 
development of variceal bleeding, ascites and hepatic 
encephalopathy. A survival analysis was conducted to 
extrapolate 12- month to 24- month mortality for the 
refractory ascites indication. Uncertainty was analysed 
in deterministic and probabilistic sensitivity analyses.
Results TIPSS was cost- effective (dominant) and cost 
saving for both indications. For variceal bleeding, pre- 
emptive TIPSS resulted in 0.209 additional QALYs, and 
saved £600 per patient compared with EBL. TIPSS had 
a very high probability of being cost- effective (95%) but 
was not cost saving in scenario analyses driven by rates 
of variceal rebleeding. For refractory ascites, TIPSS 
resulted in 0.526 additional QALYs and saved £17 983 
per patient and had a 100% probability of being cost- 
effective and cost saving when compared with LVP.
Conclusions TIPSS is a cost- effective intervention for 
variceal bleeding and refractory ascites. TIPSS is highly 
cost- saving for refractory ascites. Robust randomised 
trial data are required to confirm whether pre- emptive 
TIPSS is cost saving for variceal bleeding.
BACKGROUND
Cirrhosis of the liver imposes a substantial 
and increasing health burden being respon-
sible for 2.4% of all deaths in the UK.1 The 
NHS cost of liver disease were forecast 
to exceed £1 billion in 2015–2016.2 The 
majority of the clinical and economic burden 
in cirrhosis occurs in patients with decom-
pensated cirrhotic disease, the most common 
clinical manifestations of which are recurrent 
Summary box
What is already known about this subject?
 ► Pre- emptive transjugular intrahepatic portosystemic 
stent shunt (TIPSS) is considered to be clinically effec-
tive versus endoscopic band ligation (EBL) plus drug 
therapy in patients with cirrhosis and variceal bleeding 
who are haemodynamically stable. TIPSS is also clini-
cally effective versus large volume paracentesis (LVP) 
plus human albumin in the management of patients 
with cirrhosis and refractory ascites.
 ► Robust economic analysis with regard to use of 
TIPSS for these clinical indications is lacking.
What are the new findings?
 ► Economic modelling, using methodology endorsed 
by National Institute for Health and Care Excellence 
(NICE), found that pre- emptive TIPSS was likely to 
be cost- effective in patients with cirrhosis and var-
iceal bleeding versus treatment with EBL and beta 
blockers. However, there are high levels of uncer-
tainty as to whether TIPSS is cost- saving in the con-
text of the National Health Service (NHS).
 ► TIPSS was cost- effective as well as cost saving when 
compared with LVP plus albumin in patients with cir-
rhosis and refractory ascites. Substantial cost savings 
to the NHS are forecast from a reduced need for con-
tinued LVP sessions to drain ascitic fluid.
How might it impact on clinical practice in the 
foreseeable future?
 ► The evidence from this study supports the continued 
use of TIPSS in patients with cirrhosis and refractory 
ascites. Further well- conducted multicentre trials 
are required to confirm the cost saving potential of 
TIPSS for the variceal bleeding indication.
 ► These results could be used to revise recommen-
dations made by commissioners and inform regula-
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variceal bleeding and recurrent and refractory ascites 
(RA).3 Both variceal bleeding and RA are associated with 
significant impairment in length and quality of life.4–6
Treatment options for variceal bleeding and ascites 
include endoscopic band ligation (EBL) and large- 
volume paracentesis (LVP), respectively. Both indica-
tions can also be managed by transjugular intrahepatic 
portosystemic stent shunt (TIPSS). TIPSS procedures 
were originally conducted using bare metal stents, but 
these had relatively poor patency, requiring re- interven-
tions and are associated with an increase in the incidence 
of hepatic encephalopathy (HE).7 Clinical outcomes 
have improved since the early 2000s following the intro-
duction of expanded polytetrafluoroethylene (ePTFE) 
covered stents.7–9
When compared with EBL, randomised controlled 
trial (RCT) evidence indicates TIPSS with an ePTFE 
covered stent is likely to be clinically effective if delivered 
as a pre- emptive procedure in populations with haemo-
dynamically stable variceal bleeding. Conclusive RCT 
evidence has identified increased survival and reduced 
cirrhosis related adverse event rates for TIPSS vs LVP in 
RA populations.10 11 Such findings informed UK clinical 
guidelines which recommend TIPSS with covered stents 
for the management of variceal bleeding and RA in these 
patient populations.12 13
While TIPSS improves health morbidity and mortality, 
the procedure incurs substantial healthcare costs and 
is delivered to populations with relatively severe disease 
and poor long- term prognosis.10 11 It is questionable 
whether TIPSS offers value for money when compared 
with other interventions that could be funded within the 
budget constrained UK health sector. There is a paucity 
of evidence establishing the cost- effectiveness of TIPSS 
with ePTFE covered stents for variceal bleeding and RA 
in the UK.14 Uncertainty regarding the cost- effectiveness 
of TIPSS may be reflected in National Institute for Health 
and Care Excellence (NICE) guidelines which include 
‘consider’ rather than ‘offer’ recommendation for TIPSS 
for RA.14–16
The aim of this study was to examine the cost- 
effectiveness of TIPSS using ePTFE covered stents in the 
UK, for the following indications:
 ► Indication 1: Patients with cirrhosis, haemodynami-
cally stable variceal bleeding and moderate to severe 
hepatic dysfunction. Pre- emptive TIPSS is delivered 
within the first 72 hours of the index bleed following 
first- line EBL and drug therapy. The comparator is 
continued EBL and drug therapy.
 ► Indication 2: Patients with cirrhosis and RA. The 
comparator is LVP plus albumin.
METHODOLOGY
A cost- utility analysis was conducted for a UK popula-
tion adopting methods specified by NICE16 including 
costs incurred by the NHS and personal social services 
and health benefits measured as quality- adjusted life 
years (QALYs). The incremental cost- effectiveness ratio 
(ICER) of TIPSS versus standard care was estimated 
using a cost- effectiveness threshold of £20 000/QALY. A 
discount rate of 3.5% was applied to costs and QALYs.16 
The impact of TIPSS on healthcare resources, primarily 
hospital bed- days, was also reported.
Authors DT, GA and DP provided expert clinical advice 
as key opinion leaders (KOLs) to:
 ► Validate the model structure, treatment pathways, 
clinical data and model parameters for TIPSS and 
standard care.
 ► Provide costs where no published data were available.
Economic model
A Markov model was developed with health states of ‘alive’ 
and ‘dead’, over a 2- year time horizon, with cycle lengths 
equal to 1 month with a half- cycle correction (figure 1). 
Monthly all- cause mortality rates were estimated based on 
survival curves sourced from RCT evidence. Key adverse 
events associated with liver cirrhosis were assigned per 
cycle to the ‘alive’ population based on monthly proba-
bilities. Three adverse events were assigned to all popu-
lations: variceal bleeding, recurrent and RA and HE, 
classified as mild (grade I or II) or severe (grade III or 
IV).17 Shunt dysfunction was included as a procedure- 
related adverse event for TIPSS. Spontaneous bacterial 
peritonitis (SBP) and catheter failure were included as 
adverse events for RA populations receiving standard 
care. To avoid double counting, we did not include 
specific mortality risk per adverse event as these were 
captured within the all- cause rates.
Prior to entering the model, TIPSS populations were 
assigned to a treatment pathway based on procedural 
technical success rates. Where TIPSS resulted in a tech-
nical failure, patients entered the standard care arm.
In both arms, the following are summed:
 ► Total costs of: relevant diagnostics, treatments, 
follow- up and management of complications/adverse 
events.
 ► Total QALYs.
Population and clinical pathways
The analysis was conducted for two indications recom-
mended by UK clinical guidelines for TIPSS.12–15
Figure 1 Structure of the Markov model. QALY, quality- 
adjusted life year; RA, refractory ascites; SBP, spontaneous 
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Indication 1
Patients with cirrhosis and variceal bleeding who were 
haemodynamically stable. Populations received a pre- 
emptive TIPSS procedure within 72 hours of the index 
bleed, following first- line treatment with EBL and 
pharmaceuticals. The population were age 18 or over 
including both Child’s C and B disease with a maximum 
score of 13. Patients in whom acute variceal bleeding was 
refractory to endoscopic and pharmacological measures 
who received salvage TIPSS were excluded. The compar-
ator, standard care, comprised of:
 ► Four outpatient EBL sessions, during the first 2 
months
 ► Three follow- up outpatient EBL sessions at 6, 12 and 
24 months.
 ► A beta- blocker (either carvedilol, propranolol or 
nadolol).
Indication 2
Patients with cirrhosis and RA. Refractory status was 
defined as per UK guidelines, that is, ascites that cannot 
be mobilised or early recurrence of which (after thera-
peutic paracentesis) cannot be prevented by medical 
therapy.13 TIPSS was performed as an elective inpatient 
procedure following initial treatment with LVP. The 
comparator, standard care, comprised of further LVP 
and albumin. KOLs advised that patients in standard care 
with RA would require LVP sessions every 14 days.
In both indications, common exclusion criteria for 
TIPSS included: significant pulmonary hypertension, 
heart failure, rapidly progressing liver failure, severe or 
uncontrolled HE, sepsis, unrelieved biliary obstruction, 




Clinical parameters were identified through a 
systematic literature review (online supplemental 
appendix 1).18 In summary, an electronic literature 
search was conducted for clinical, safety and economic 
studies of TIPSS in portal hypertension, oesophageal 
and gastric varices and ascites. After deduplication, 5502 
remained for screening, 5209 were excluded at title and 
abstract review, with 293 included for full text review. In 
total, 10 RCTs and 10 economic studies were identified.
Indication 1—variceal bleeding
Base case parameter values were informed predominantly 
by the Garcia- Pagán et al RCT.10 The study reported actu-
arial probabilities of survival at 12 months equal to 86% 
(TIPSS) and 61% (EBL), with no additional mortality 
reported between months 12 and 24. Probabilities 
for adverse events were obtained at 12- month and/or 
24- month endpoints as reported by Garcia- Pagán et al.10
Indication 2—refractory ascites
Bureau et al was considered to be the most relevant 
RCT, reporting 12- month actuarial survival curves for 
TIPSS versus LVP in RA.11 We calculated survival proba-
bilities at 24 months by constructing parametric survival 
curves with a log normal survival function based on the 
12- month patient data in Bureau et al (online supple-
mental appendix 2).11
Clinical parameter values are reported in table 1. All 
values were converted to rates per month to align with 
the model’s cycle duration. Where published data were 
only available across a 12- month time horizon, monthly 
event rates for months 1–12 were applied across the full 
24 months. All data were obtained from RCTs or meta- 
analyses excluding two observational studies which 
informed the technical success rate for TIPSS, equal to 
98%,19 and the rate of catheter failure for patients with 
LVP equal to 3.8%.20 In addition, we followed methods 
by Shen et al21 and applied a conservative assumption 
for the rate of recurrent bleeding for TIPSS patients in 
the RA indication, set equal to 4.4% as opposed to 0% in 
Bureau et al.11
Healthcare resource usage and unit costs
TIPSS and standard care
We conducted pragmatic literature searches of UK and 
European clinical guidelines and economic studies to 
identify resource use and unit costs. Resources required 
for the preoperative, intraoperative and postoperative 
phases of TIPSS were extracted from UK clinical guide-
lines.12 13 The KOLs estimated an average length of stay 
equal to 2 days per elective and 5 days per non- elective 
TIPSS. Costs per excess bed day were calculated from 
NHS reference costs as weighted average across TIPSS 
tariffs YR16A and YR16B.22 Resources for standard 
care were identified from published literature, with 
KOLs advising on consistency with UK clinical practice. 
Unit costs were from national databases,22–24 with gaps 
informed by the KOLs. The model used 2017/2018 
prices. Dossiers reporting the resources and unit cost 
were reviewed by KOLs, in an iterative process, until a 
consensus was reached.
Resource and unit cost for TIPSS and standard care 
are summarised in table 2 and fully detailed in online 
supplemental appendix 3. TIPSS for variceal bleeds were 
non- elective, costing £5398; TIPSS for RA were elec-
tive, costing £4646 per procedure. All cases of technical 
failure had an additional procedure time of 2 hours and 
required an additional VIATORR stent. In comparison, 
standard care costs for variceal bleeding (EBL plus beta- 
blockers) were £3862, per patient assuming 24- month 
survival. Standard care costs for RA were £800 per LVP 
session, occurring every 14 days, summing to £41 618 per 
patient assuming 24- month survival.
Complications and adverse events
Table 2 and online supplemental appendix 3 detail the 
treatment assumptions applied per adverse event. In 
brief, a TIPSS shunt dysfunction required reintervention 
with a balloon catheter costing £4095. Variceal bleeding 
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inpatient/emergency hospital stay and cost £3081. Fifty 
per cent of variceal bleeding episodes for patients with 
RA were treated with TIPSS, 14% received a further EBL 
session and 36% were managed by watchful waiting, 
giving an average cost of £6454 per episode.
Uncomplicated moderate ascites13 were treated with 
spironolactone (£5.90), while uncomplicated large ascites 
required 1.2 sessions with LVP and albumin (£960).
Lactulose (1 month) and rifaximin (6 months) to treat 
mild HE (grade I & II) cost £91 per month. Twenty- five 
per cent of severe HE (grade III and IV) cases received 
a TIPSS reduction procedure, with the remainder 
managed on rifaximin for 6 months, giving an average 
cost of £1377.
Antibiotics, albumin and hospital bed- days per SBP 
episode were estimated to cost £1308, while catheter 
failure was estimated to cost £552.
Utilities
Utility values were identified through a pragmatic litera-
ture search, including handsearching of the 10 retrieved 
economic studies. Baseline utilities for the bleeding 
indication were 0.67 for Child- Pugh B and 0.56 for 
Child- Pugh C.25 We applied population weightings by 
Child- Pugh B/C in line with the Garcia- Pagan (2010) 
RCT population,10 resulting in a baseline utility for vari-
ceal bleeding of 0.62.
A baseline utility of 0.65 for people with liver cirrhosis 
without ascites was obtained from Moscucci et al.26
Disutilities were applied to each adverse event. Disut-
ilities of 0.15 for TIPSS procedures, including shunt 
dysfunction were applied during the hospital stay.27 All 
other disutilities were applied to the full month cycle and 
are reported in table 2.
Sensitivity and scenario analyses
Extensive deterministic sensitivity analysis (DSA) was 
conducted across ranges equal to the 95% CI or ±15% 
of the mean if CIs were unavailable. Results were plotted 
on Tornado diagrams to identify key drivers of cost- 
effectiveness. Threshold analyses for several influential 
parameters determined the lower/upper bounds for 
TIPSS to be cost- effective and cost saving vs standard care.
Probabilistic sensitivity analysis (PSA) was conducted 
using 10 000 iterations to establish the uncertainty in the 
cost- effectiveness results given the combined uncertainty 
of the parameter values. All probabilistic parameter 
distributions followed recommendations by Briggs et al 
(online supplemental appendix 4).28
Scenario analyses were conducted for the vari-
ceal bleeding indication using clinical parameters 
from a random effects meta- analysis (online supple-
mental appendix 1), which pooled values from 
Garcia- Pagán et al10 and a recent UK RCT by 
Dunne et al.29 The meta- analysis was not used as the 
base case due to a high risk of bias in Dunne et al where 
only 13 of 29 participants received ‘early’ TIPSS within 
72 hours. As outlined in the Cochrane risk- of- bias tool 





TIPSS Standard care Source TIPSS Standard care Source
Survival at 12 months 0.860 0.610 10 0.928* 0.553* 11
Survival at 24 months 0.860 0.610 10 0.890* 0.241* 11
TIPSS technical success 0.980 N/A 19 0.980 N/A 19
Shunt dysfunction 0.070 N/A 40 0.030 N/A 11
Variceal bleeding at 12 months 0.030 0.500 10 0.044† 0.182 21; 11
Variceal bleeding at 24 months 0.030 0.500 10 Assume same rates as 12 months
Ascites at 12 months 0.130 0.330 10 0.510 1.000 41
HE at 12 months 0.280 0.400 10 0.345 0.333 11
% HE severe‡ 0.250 0.250 KOLs 0.400 0.636 11
SBP at 12 months N/A N/A N/A N/A 0.060 11
Catheter failure at 12 months N/A N/A N/A N/A 0.038§ 20
*Survival rates for indication 2 were obtained by estimating parametric survival curves with a lognormal survival function, using 12- month 
patient data reported in Bureau et al. For further details, see online supplemental appendix 2).
†Conservative assumption applied as per economic evaluation of TIPSS for RA by Shen et al.21 The rate of variceal bleeding from Bureau et 
al is equal to 0% for TIPSS and 18.2% for standard care.11
‡Absolute % of severe HE calculated as overall HE rate multiplied by % HE severe. The remaining HE episodes are classified as mild. % of 
severe HE obtained from: KOL assumption for variceal bleeding; Bureau et al11 as number of OHE episodes grade >2/total number of OHE 
episodes.
§% with catheter failure at 12 months obtained by extrapolating value from source at 41 weeks (3%), assuming proportional rates between 
weeks 41 and 52.
HE, hepatic encephalopathy; KOL, key opinion leader; N/A, not applicable; RA, refractory ascites; SBP, spontaneous bacterial peritonitis; 
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for RCTs, deviations from the intended interventions 
can lead to heterogeneity in meta- analyses of intention- 
to- treat studies.30 Consequently, two scenario analyses 
were conducted where the meta- analyses included 
(i) intention- to- treat and (ii) per- protocol data from 
Dunne et al.29 The clinical parameters for each scenario 
are presented in table 3; all other parameters retain 
the values reported in table 1.
In the RA indication, a scenario analysis was 
conducted reducing the frequency of LVP sessions 
from 2.17 per month to 0.71 per month, this value 
being informed by findings from a UK observational 
study by Parker et al.31 In addition, two scenario anal-
yses were conducted which applied the Weibull and 
exponential distributions as the parametric function 
used to estimate 24- month survival as opposed to the 
log normal distribution used in the base case analysis 
(online supplemental appendix 2).
RESULTS
Results from the base- case and scenario analyses are 
reported in table 4, with Tornado diagrams presented 
in online supplemental appendix 5.
TIPSS for variceal bleeding
In the base case analysis, TIPSS had 0.209 additional 
QALYs and NHS savings of £600 per person when 
compared with EBL and pharmaceuticals. Hence, TIPSS 
dominated standard care. Savings were predominantly 
related to treatment (£4059) and hospital stay (£1949) 
for recurrent bleeding episodes. NHS savings due to 
reductions in adverse events outweighed the average cost 
of £5613 per patient for a TIPSS procedure and subse-
quent hospital stay. The major resource saving (per 1000 
population) was 400 fewer bed- days for TIPSS compared 
with standard care (23 vs 424). There were also fewer HE 
events (44 vs 52), ascites events (25 vs 55) and angiogra-
phies (4 vs 53).
TIPSS remained cost- effective for both scenario anal-
yses, but was no longer cost saving. The incremental 
costs of TIPSS was equal to £445 (scenario 1) and £372 
(scenario 2) while incremental QALYs were equal to 0.21 
(scenario 1) and 0.22 (scenario 2). The resultant ICERs 
for scenarios 1 and 2 were well below the £20 000/QALY 
threshold and equal to £4128 and £3267, respectively.
The base case results were also sensitive to changes in 
EBL survival rates, TIPSS procedural costs and the cost 
and frequency of EBL procedures. TIPSS was cost incur-
ring for these DSAs but cost saving for all others. In all 
DSAs, ICERs remained below £20 000/QALY. Threshold 
analyses established that TIPSS would remain cost- saving 
if the frequency of outpatient EBL procedures for the 
initial bleed reduced from 4.00 to 2.82, the technical 
success rate for TIPSS reduced from 98% to 88%, and 
if the cost per non- elective bed day for TIPSS patients 
increased from £442 to £995.
PSA results are displayed in figure 2. TIPSS was 
cost- effective in 95% and cost- saving in 75% of 10 000 
iterations.
Table 2 Resource usage, unit and total costs (2017/2018 
prices) and utilities
  Units Costs Source
TIPSS procedure
  TIPSS procedure plus 
consumables
1.00 £2353 KOLs; Gore
  Diagnostic tests (elective only) 3.13 £396 KOLs22
  Pre- procedure HCP (hours) 0.33 £36 KOLs24
  Procedure HCP (hours) 14.00 £796 KOLs24
  Hospital stay (elective) days 2.00 £1064 KOLs22
  Hospital stay (non- elective) days 5.00 £2212 KOLs22
  Total (elective) £4646   
  Total (non- elective) £5398   
Standard care: indication 1 
(variceal bleeding)
  Outpatient EBL (months 1–2) 4.00 £2177 KOLs22
  Outpatient EBL (months 3–24) 3.00 £1633 KOLs22
  Pharmaceuticals (per month) Various £4.42 23
  Total costs (24 month survival) £3862   
Standard care: indication 2 (refractory ascites)
  LVP per procedure
  Consumables/sundries 1.00 £180 42
   HCP time (nurse: hours) 0.50 £19 KOLs22
   Human albumin (dose 52 mg) 1.00 £34 KOLs23
   Hospital stay 1.90 £568 KOLs22
  Cost per LVP +human albumin 1.00 £800   
  Total cost (24- month survival) 52.00 £41 618
  Total cost Disutility
Source 
(utility)





Shunt dysfunction* £4095 0.010 27
Variceal bleeding† 27
  TIPSS (indications 1 and 2) £,3081 0.154
  Standard care (indication 1) £6454 0.154
  Standard care (indication 2) £3081 0.154
Ascites† 26
  Uncomplicated, moderate £6 0.125
  Uncomplicated, large £960 0.125
Hepatic Encephalopathy 32
  Mild HE (grade I and II)† £91 0.070
  Severe HE (grade III and IV)† £1377 0.130
SBP† £1308 0.120 43
Catheter failure £552 0.000‡ N/A
Cost components and sources are reported in full in online supplemental appendix 3.
*Utility decrement applied only to length of hospital stay.
†Utility decrement applied to full cycle (monthly per event rate).
‡Utility decrement equal to zero as no published evidence to the contrary.
EBL, endoscopic band ligation; HCP, healthcare provider; HE, hepatic encephalopathy; 
KOL, key opinion leader; LVP, large vol paracentesis; SBP, spontaneous bacterial 
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TIPSS for refractory ascites
In the base- case analysis, TIPSS resulted in 0.526 addi-
tional QALYs and NHS savings of £17 983 per patient 
versus LVP. Hence, TIPSS dominated standard care. 
TIPSS substantially increased survival resulting in 0.630 
incremental life- years gained per patient. The major 
savings were from avoided LVP sessions. Each person 
treated with LVP incurred £22 322 additional costs to 
manage ascites over 24 months. These exceeded the 
average cost of £4877 per patient for a TIPSS procedure. 
TIPSS also saved £452 from fewer variceal bleeds, £116 
from reduced cases of SBP and £116 from fewer cath-
eter failures; however, there was an increase of £31 for 
HE (table 3). The major resource saving for TIPSS versus 
LVP (per 1000 population) was 4550 fewer bed- days (446 
vs 4996). There were also fewer recurrent bleeds (9 vs 
15) but more episodes of mild HE (49 vs 17). SBP and 
catheter failure had event rates of 7 and 5, respectively, 
in standard care.1
Results were robust across all DSA scenarios with 
TIPSS remaining cost saving. This included scenarios 
which reduced the frequency of LVP sessions from 2.17 
per month to 0.71 per month, consistent with findings 
from an observational study by Parker et al31 and applied 
different functions to estimate 24- month survival (online 
supplemental appendix 2).
PSA results are displayed in figure 2. TIPSS was cost- 
saving in all 10 000 iterations. There was, however, uncer-
tainty in the value of cost savings associated with TIPSS 
which ranged substantially from a minimum of £29 to a 
maximum of £46 608.
DISCUSSION
Key findings
Our analysis suggests that TIPSS with an ePTFE covered 
stent is cost- saving and cost- effective in the UK, for 
patients with cirrhosis and variceal bleeding or RA. The 
results are driven by reductions in reinterventions for 
bleeding and RA. In particular, TIPSS was highly cost- 
saving for the RA indication, including across all sensi-
tivity analyses.
While TIPSS was dominant (QALY gains and cost 
savings) in the base case for the bleeding indication, 
TIPSS was not cost saving in either of the scenario 
analyses. The uncertainty was due to large differences in 
recurrent bleeding rates (base case: 3% TIPSS, 50% stan-
dard care; scenario 1: 7% TIPSS, 36.7% standard care; 
scenario 2: 2.9% TIPSS, 36.7% standard care) which 
accounted for 86% of the total difference in NHS costs 
between scenarios. We suggest that further research is 
required to support robust economic modelling results 
for this indication.
Consistency with other studies
Our economic searches did not identify any UK- based 
cost- utility analyses indicating this is the first UK 
economic evaluation of ePTFE covered stents for either 
indication. Our results are in line with two cost- utility 
analyses conducted in the USA, by Shen et al21 and Kwan 
et al,32 where TIPSS was highly cost- effective, although 
neither found TIPSS to be cost- saving. Differences may 
have occurred due to the shorter time horizon (1 year) 
adopted by Shen et al,21 and the use of bare metal stents 
studies to inform clinical parameters by Kwan et al.32
Our results in RA are consistent with a real- world retro-
spective cost analysis by Parker et al of 24 TIPSS patients 
with RA managed at an NHS hospital.31 Mean savings 
using TIPSS as opposed to LVP with albumin were £2759 
per person (2012/2013 prices) which increased to £4570 
per person when removing an outlier.31 Cost savings were 
higher for TIPSS in our analysis (£17 983) due to larger 
number of LVP sessions, equal to 2.17 per month. When 
reducing the number of LVP sessions to 0.71 per month, 
as observed by Parker et al,31 we identified similar levels of 
cost savings for TIPSS, equal to £2053.
Limitations
There was considerable uncertainty in the cost- 
effectiveness of pre- emptive TIPSS compared with EBL 
for the bleeding indication due to limitations in the clin-
ical evidence. It was not considered appropriate to use 
the meta- analysis for the base case analysis due to the 
high risk of bias associated with the Dunne et al29 study; 
thus, the clinical parameters were informed predomi-
nantly from a single RCT.10
A major concern regarding the study by Garcia- Pagán 
et al10 is the small sample (n=63) and imprecise param-
eter values. In particular, the rate of variceal bleeding 
for TIPSS versus EBL had a 95% CI ranging from 25% 
Table 3 Clinical outcomes used in scenario analyses for variceal bleeding
Scenario 1 Scenario 2
TIPSS Standard care TIPSS Standard care
Survival at 12 months 0.827 0.683 0.834 0.683
Survival at 24 months 0.827 0.683 0.834 0.683
Variceal bleeding at 12 months 0.070 0.367 0.029 0.367
Variceal bleeding at 24 months 0.070 0.367 0.029 0.367
Ascites at 12 months 0.230 0.380 0.160 0.290
HE at 12 months 0.340 0.280 0.360 0.280
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to 69%. Imprecision in the clinical parameters did not 
translate to high levels of uncertainty in the PSA, where 
TIPSS had a 95% and 75% probability of being cost- 
effective and cost- saving, respectively. However, in our 
most pessimistic scenario, application of the lower 95% 
CI changed the result of the cost analysis where TIPSS 
became cost incurring to the NHS.
A second concern relates to improvements in standard 
care, including survival, since the Garcia- Pagán et al10 
RCT.33 Propranolol was used in the standard care arm10 
while Dunne et al29 adopted more recent practice with 
62% of patients treated with carvedilol. The latter may 
have a greater effect on portal pressure although there 
are no data to confirm this in secondary prophylaxis. This 
and other improvements in cirrhosis care may account for 
some of the increased survival observed between the two 
studies, rising from 61%10 to 76%.29 Increased survival 
for standard care may not impact the cost- effectiveness 
results materially as survival for TIPSS patients is likely to 
substantially exceed current standard care.
A third concern relates to patient selection. Our results 
are not specific by Child- Pugh classification as in Garcia- 
Pagan (2010) about half of patients were class B and half 
class C.10 A recent editorial noted several observational 
studies have shown survival benefit of TIPSS in Child‐C 
but not in Child‐B patients, regardless of active bleeding. 
It concluded that large multicentre RCTs are necessary to 
draw firm conclusions on survival benefit of TIPSS in all 
high‐risk groups.34
The RA indication was also limited by the use of the 
single study by Bureau et al11 to inform the majority of 
parameter values. Again, there were limitations with 
study size (n=62) and also generalisability of French 
data to the UK setting. Any biases in the RCT design 
will be applicable to the economic results, for example, 
alcohol cessation is identified as a potential confounder 
for improved liver function by Bureau et al.11 In addition, 
Bureau et al11 excluded patients requiring  LVPs within 
the previous 3 months. Our base- case analysis modelled 
patients who require six LVPs every 3 months and thus 
at the extreme range of disease severity included in the 
RCT, but this was supported by KOL opinion. Uncer-
tainties in the clinical parameters did not, however, 
translate to decision uncertainty for the RA indication: 
TIPSS remained dominant across all sensitivity analyses 
and was cost- effective and cost- saving in 100% of the 
PSA iterations.
There was additional uncertainty in other parameter 
values. For the bleeding indication, TIPSS was cost- 
effective but not cost- saving when follow- up EBL sessions 
during the first 2 months for standard care were reduced 
below 2.82. Dunne (2020)29 report a median of 4 (range 
0 to 8) elective EBL procedures over 12 months for 29 
patients receiving standard care; however, this outcome 
was not well reported and may not be directly comparable 
to the number of EBL sessions in our model which are 
conditional on survival. Across both indications, no inter-
vention specific utilities were applied and all included 
values came from low quality and somewhat dated studies 
that did not apply the EQ- 5D measure preferred in the 
NICE reference case. However, the values are reason-
ably consistent with the recent NICE cirrhosis guideline 
which reported no difference in utilities between TIPSS 
and LVP.14
Finally, our analysis relied on tariff price for the esti-
mation of in- hospital costs separately for elective (suit-
able for indication 1 including ICU bed occupancy) 
and non- elective TIPSS admissions. There may have 
been relevant costs that were not captured within the 
tariff such as patient transfer for TIPSS. The cost per 
bed day threshold analysis indicates tariff excluded 
costs need to be substantial to alter the findings as such 
costs are also applicable to recurrent bleeding episodes 
which have higher rates in standard care.
Future research
Management of the complications of decompensated 
cirrhosis remains an area of intense research and 
the treatment landscape is evolving for both indica-
tions. For variceal bleeding, the ongoing CALIBRE 
trial compares carvedilol with EBL in a multicentre 
UK setting,35 while the benefits of long- term albumin 
in RA has been reported in the ANSWER trial.36 The 
ePTFE covered stent has also evolved, with a controlled 
expansion feature. Early studies of the device suggest 
improved outcomes for survival and lower adverse 
events, particularly HE and cardiac complications, 
Figure 2 PSA results. PSA, probabilistic sensitivity analysis; 
QALY, quality- adjusted life year; CE, cost- effectiveness. by copyright.
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which may be due to the improved haemodynamic 
control of the ePTFE covered stent.37–39
Future economic models will require robust clinical 
evidence. Future studies should prioritise the inclu-
sion of patients who are treated with contemporaneous 
standard of care and be powered sufficiently to detect 
differences on key clinical outcomes. It is critical that 
clinical trials capture aspects of the service delivery 
of TIPSS at national level, including optimal volume 
of procedures, in a multicentre format. Further cost- 
effectiveness evidence by Child- Pugh subgroup should 
be obtained when robust clinical evidence becomes 
available. Analyses would be enhanced by the avail-
ability of validated utility or mapped quality of life 
values.
CONCLUSION
Using the best available evidence, our study indicates that 
TIPSS with an ePTFE covered stent improves survival and 
is cost- effective for the two indications. There is a very high 
likelihood of TIPSS being cost saving for populations with 
RA. There is considerably less certainty that pre- emptive 
TIPSS is cost saving for populations with haemodynam-
ically stable variceal bleeding. An adequately powered 
RCT capturing the current treatment landscape and 
quality of life is required to inform robust modelling, 
particularly for the bleeding indication.
Author affiliations
1York Health Economics Consortium, University of York, York, UK
2Liver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS 
Foundation Trust, Birmingham, UK
3Associate, W.L. Gore and Associates, Livingston, UK
4Hepatology and Liver Transplantation, Royal Free London NHS Foundation Trust, 
London, UK
5Faculty of Medicine & Health Sciences, The University of Nottingham, Nottingham, 
UK
Acknowledgements We thank Thomas Weierma (W.L. Gore and Associates, 
Tilburg, Netherlands) who supported the study, providing input to the patient 
pathways, cost inputs and commented on drafts of the manuscript.
Contributors RM: primary author of manuscript and involved in all stages of 
research including model design, build, review of clinical and economic evidence. 
FON: involved in design of the study, analysis and interpretation of data; reviewed 
and edited the manuscript and primary author of several paragraphs. JC: involved 
in design of the study, analysis and interpretation of data; reviewed and edited the 
manuscript and primary author of several paragraphs. JT: involved in review of the 
economic model design and clinical evidence; reviewed and edited the manuscript. 
DT, DP, GA: provided key clinical input for this research; acted as key opinion 
leaders (KOLs) and informed parameter values and provided validation for the 
model design; reviewed and edited the manuscript.
Funding This work was funded by W.L. Gore & Associates. W.L. Gore & Associates 
were involved in the design of the study, data collection, analysis and interpretation 
of data as well as the writing of the manuscript.
Competing interests RM is an employee of York Health Economics Consortium 
who were commissioned by W.L. Gore & Associates to provide consultancy, develop 
the economic model and write the manuscript.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement No data are available.
Supplemental material This content has been supplied by the author(s). It has 
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been 
peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the 
use is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iD
Richard Mattock http:// orcid. org/ 0000- 0001- 7517- 5233
REFERENCES
 1 SepanlouSG, SafiriS, BisignanoC, et al. The global, regional, and 
national burden of cirrhosis by cause in 195 countries and territories, 
1990-2017: a systematic analysis for the global burden of disease 
study 2017. Lancet Gastroenterol Hepatol 2020;5:245–66.
 2 Dorrell S. Government’s alcohol strategy: third report of session 
2012-13, Vol. 1: Report. together with formal minutes oral and 
written evidence: The Stationery Office; 2012.
 3 Desai AP, Mohan P, Nokes B, et al. Increasing economic burden in 
hospitalized patients with cirrhosis: analysis of a national database. 
Clin Transl Gastroenterol 2019;10:e00062.
 4 Hudson B, Round J, Georgeson B, et al. Cirrhosis with ascites in 
the last year of life: a nationwide analysis of factors shaping costs, 
health- care use, and place of death in England. Lancet Gastroenterol 
Hepatol 2018;3:95–103.
 5 Jepsen P, Ott P, Andersen PK, et al. Clinical course of alcoholic 
liver cirrhosis: a Danish population- based cohort study. Hepatology 
2010;51:1675–82.
 6 Labenz C, Toenges G, Schattenberg JM, et al. Health- Related 
quality of life in patients with compensated and decompensated liver 
cirrhosis. Eur J Intern Med 2019;70:54–9.
 7 Saad WE. The history and future of transjugular intrahepatic 
portosystemic shunt: food for thought. Semin Intervent Radiol 
2014;31:258–61.
 8 Bureau C, Garcia Pagan JC, Layrargues GP, et al. Patency of 
stents covered with polytetrafluoroethylene in patients treated by 
transjugular intrahepatic portosystemic shunts: long- term results of 
a randomized multicentre study. Liver Int 2007;27:742–7.
 9 Perarnau JM, Le Gouge A, Nicolas C, et al. Covered vs. uncovered 
stents for transjugular intrahepatic portosystemic shunt: a 
randomized controlled trial. J Hepatol 2014;60:962–8.
 10 García- Pagán JC, Caca K, Bureau C, et al. Early use of TIPS in 
patients with cirrhosis and variceal bleeding. N Engl J Med Overseas 
Ed 2010;362:2370–9.
 11 Bureau C, Thabut D, Oberti F, et al. Transjugular intrahepatic 
portosystemic shunts with covered stents increase transplant- 
free survival of patients with cirrhosis and recurrent ascites. 
Gastroenterology 2017;152:157–63.
 12 Tripathi D, Stanley AJ, Hayes PC, et al. Transjugular intrahepatic 
portosystemic stent- shunt in the management of portal 
hypertension. Gut 2020;69:1173–92.
 13 Aithal GP, Palaniyappan N, China L, et al. Guidelines on the 
management of ascites in cirrhosis. Gut 2021;70:9–29.
 14 NICE. Cirrhosis in over 16s: assessment and management. NICE 
guideline [NG50]. London National Institute for Health and Care 
Excellence (NICE); 2016.
 15 NICE. Acute upper gastrointestinal bleeding in over 16s: 
management. Clinical guideline [CG141]. London National Institute 
for Health and Care Excellence (NICE); 2016.
 16 NICE. Developing NICE guidelines: the manual. Process and 
methods [PMG20]: National Institute for Health and Care Excellence 
(NICE) 2018.
 17 Weissenborn K. Hepatic encephalopathy: definition, clinical grading 
and diagnostic principles. Drugs 2019;79:5–9.
 18 Tripathi D, O’Neill F, Patch D. P59 Systematic review and meta- 
analysis of early transjugular intrahepatic portosystemic stent- 















astroenterol: first published as 10.1136/bm





10 Mattock R, et al. BMJ Open Gastro 2021;8:e000641. doi:10.1136/bmjgast-2021-000641
Open access 
 19 Perelló MP, Mur JP, Vives MS, et al. Long- Term follow- up of 
transjugular intrahepatic portosystemic shunt (TIPS) with stent- graft. 
Diagn Interv Radiol 2019;25:346–52.
 20 Rosenberg S, Courtney A, Nemcek AA, et al. Comparison of 
percutaneous management techniques for recurrent malignant 
ascites. J Vasc Interv Radiol 2004;15:1129–31.
 21 Shen NT, Schneider Y, Congly SE, et al. Cost effectiveness 
of early insertion of transjugular intrahepatic portosystemic 
shunts for recurrent ascites. Clin Gastroenterol Hepatol 
2018;16:e1503:1503–10.
 22 National schedule of reference costs 2017/18, 2018. Available: 
https:// improvement. nhs. uk/ resources/ national- cost- collection/
 23 Joint Formulary Committee. BNF 77 (British National formulary) 
March 2019. Pharmaceutical Press, 2019.
 24 PSSRU. Unit costs of health & social care, 2019. Available: https://
www. pssru. ac. uk/ project- pages/ unit- costs/ unit- costs- 2019/
 25 Younossi ZM, Boparai N, McCormick M, et al. Assessment of utilities 
and health- related quality of life in patients with chronic liver disease. 
Am J Gastroenterol 2001;96:579–83.
 26 Moscucci F, Nardelli S, Pentassuglio I, et al. Previous overt hepatic 
encephalopathy rather than minimal hepatic encephalopathy 
impairs health- related quality of life in cirrhotic patients. Liver Int 
2011;31:1505–10.
 27 Wechowski J, Connolly M, Woehl A, et al. An economic evaluation 
of vasoactive agents used in the United Kingdom for acute bleeding 
oesophageal varices in patients with liver cirrhosis. Curr Med Res 
Opin 2007;23:1481–91.
 28 Briggs A. Probabilistic analysis of cost- effectiveness models: 
statistical representation of parameter uncertainty. Value Health 
2005;8:1–2.
 29 Dunne PDJ, Sinha R, Stanley AJ, et al. Randomised clinical trial: 
standard of care versus early- transjugular intrahepatic porto- 
systemic shunt (TIPSS) in patients with cirrhosis and oesophageal 
variceal bleeding. Aliment Pharmacol Ther 2020;52:98–106.
 30 Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for 
assessing risk of bias in randomised trials. BMJ 2019;366:l4898.
 31 Parker MJ, Guha N, Stedman B, et al. Trans- jugular intrahepatic 
porto- systemic shunt placement for refractory ascites: a 'real- 
world' UK health economic evaluation. Frontline Gastroenterol 
2013;4:182–6.
 32 Kwan SW, Allison SK, Gold LS, et al. Cost- Effectiveness of 
transjugular intrahepatic portosystemic shunt versus large- volume 
paracentesis in refractory ascites: results of a Markov model 
incorporating individual patient- level meta- analysis and nationally 
representative cost data. J Vasc Interv Radiol 2018;29:1705–12.
 33 Schmidt ML, Barritt AS, Orman ES, et al. Decreasing mortality 
among patients hospitalized with cirrhosis in the United States from 
2002 through 2010. Gastroenterology 2015;148:e962:967–77.
 34 Khan F, Tripathi D. Early TIPSS in patients with cirrhosis and acute 
variceal bleeding—the plot thickens! Wiley Online Library, 2020.
 35 Tripathi D, Hayes PC, Richardson P, et al. Study protocol for a 
randomised controlled trial of carvedilol versus variceal band ligation 
in primary prevention of variceal bleeding in liver cirrhosis (CALIBRE 
trial). BMJ Open Gastroenterol 2019;6:e000290.
 36 Caraceni P, Riggio O, Angeli P, et al. Long- Term albumin 
administration in decompensated cirrhosis (ANSWER): an open- label 
randomised trial. Lancet 2018;391:2417–29.
 37  ClinicalTrials. gov. Identifier NCT03083925, Viatorr CX case- control 
study for complications of portal hypertension (VIATORR- CX). 
Bethesda (MD) National Library of Medicine(US); 2019.
 38  ClinicalTrials. gov. Identifier NCT04315571, comparing ascites relief 
in two standard treatments: large volume paracentesis vs. early tips 
using Viatorr controlled expansion stents. Bethesda (MD) National 
Library of Medicine(US); 2019.
 39 Praktiknjo M, Abu- Omar J, Chang J, et al. Controlled underdilation 
using novel VIATORR® controlled expansion stents improves 
survival after transjugular intrahepatic portosystemic shunt 
implantation. JHEP Rep 2021;3:100264.
 40 Lv Y, Yang Z, Liu L, et al. Early TIPS with covered stents versus 
standard treatment for acute variceal bleeding in patients 
with advanced cirrhosis: a randomised controlled trial. Lancet 
Gastroenterol Hepatol 2019;4:587–98.
 41 Bai M, Qi X- S, Yang Z- P, et al. TIPS improves liver transplantation- 
free survival in cirrhotic patients with refractory ascites: an updated 
meta- analysis. World J Gastroenterol 2014;20:2704–14.
 42 Mullan D, Kibriya N, Jacob A. Draining malignant ascites at home 
with tunnelled catheters: complications and costs 2015.
 43 Badia JM, Casey AL, Petrosillo N, et al. Impact of surgical site 
infection on healthcare costs and patient outcomes: a systematic 














astroenterol: first published as 10.1136/bm
jgast-2021-000641 on 24 A
ugust 2021. D
ow
nloaded from
 
